Aclaris Therapeutics, Inc. (LON:0H8T)
1.940
-0.085 (-4.20%)
At close: Sep 12, 2025
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $1.78M USD in the quarter ending June 30, 2025, a decrease of -35.76%. This brings the company's revenue in the last twelve months to $16.79M, down -47.56% year-over-year. In the year 2024, Aclaris Therapeutics had annual revenue of $18.72M, down -40.09%.
Revenue (ttm)
$16.79M
Revenue Growth
-47.56%
P/S Ratio
11.71
Revenue / Employee
$262.33K
Employees
64
Market Cap
143.52M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Aclaris Therapeutics News
- 9 days ago - Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress - GlobeNewsWire
- 22 days ago - Aclaris Therapeutics to Participate in Two September Healthcare Conferences - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement - Benzinga
- 7 weeks ago - Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints - GlobeNewsWire
- 7 weeks ago - Aclaris Therapeutics Announces Leadership Transition - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics joins Russell 3000 and Russell 2000 Indexes - Seeking Alpha
- 2 months ago - Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewsWire